Evaluate Risk/Benefit of Nab Paclitaxel in Combination With Gemcitabine and Carboplatin Compared to Gemcitabine and Carboplatin in Triple Negative Metastatic Breast Cancer (or Metastatic Triple Negative Breast Cancer)
Public ClinicalTrials.gov record NCT01881230. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 2/3, Multi-Center, Open-Label, Randomized Study of Weekly Nab®-Paclitaxel in Combination With Gemcitabine or Carboplatin, Compared to Gemcitabine/Carboplatin, as First Line Treatment in Subjects With ER, PgR, and HER2 Negative (Triple Negative) Metastatic Breast Cancer
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The purpose of this study is to compare the safety and efficacy of nab-paclitaxel in combination with either gemcitabine or carboplatin to the combination of gemcitabine and carboplatin as first line treatment in female subjects with triple negative metastatic breast cancer (TNMBC) or metastatic triple negative breast cancer.
Study identification
- NCT ID
- NCT01881230
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2, Phase 3
- Enrollment
- 191 participants
Conditions and interventions
Conditions
- Breast Tumor
- Breast Cancer
- Cancer of the Breast
- Estrogen Receptor- Negative Breast Cancer
- HER2- Negative Breast Cancer
- Progesterone Receptor- Negative Breast Cancer
- Recurrent Breast Cancer
- Stage IV Breast Cancer
- Triple-negative Breast Cancer
- Triple-negative Metastatic Breast Cancer
- Metastatic Breast Cancer
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- Female
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Sep 26, 2013 (Actual)
- Primary completion
- Oct 28, 2016 (Actual)
- Completion
- Oct 28, 2016 (Actual)
- Last update posted
- Feb 21, 2019
2013 – 2016
United States locations
- U.S. sites
- 64
- U.S. states
- 26
- U.S. cities
- 60
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Ironwood Cancer and Research Center | Chandler | Arizona | 85224 | — |
| Arizona Center for Cancer Care | Glendale | Arizona | 85306 | — |
| Arizona Cancer Research Alliance | Scottsdale | Arizona | 85251 | — |
| Mayo Clinic Arizona | Scottsdale | Arizona | 85259 | — |
| Highlands Oncology Group | Fayetteville | Arkansas | 72703 | — |
| Pacific Cancer Medical Center Inc | Anaheim | California | 92801 | — |
| California Cancer Associates for Research and Excellence cCARE | Escondido | California | 92025 | — |
| University of California San Diego Moores Cancer Center | La Jolla | California | 92093 | — |
| Wilshire Oncology Medical Group, Inc | La Verne | California | 91750 | — |
| Translational Research Management | Los Angeles | California | 90045 | — |
| Coastal Integrative Cancer Care | San Luis Obispo | California | 93401 | — |
| Central Coast Medical Oncology Corporation | Santa Maria | California | 93454 | — |
| Redwood Regional Medical Group, INC | Santa Rosa | California | 95403 | — |
| Center for Hematology-Oncology | Boca Raton | Florida | 33486 | — |
| Memorial Breast Cancer Center | Hollywood | Florida | 33021 | — |
| Mayo Clinic - Jacksonville | Jacksonville | Florida | 32224 | — |
| University of Miami School of Medicine | Miami | Florida | 33136 | — |
| Florida Cancer Specialists | Sarasota | Florida | 34232 | — |
| Florida Cancer Specialists | St. Petersburg | Florida | 33705 | — |
| Florida Cancer Specialists | West Palm Beach | Florida | 33401 | — |
| Joliet Oncology-Hematology Associates, Ltd | Joliet | Illinois | 60435 | — |
| Carle Cancer Center | Urbana | Illinois | 61801 | — |
| Investigative Clinical Research of Indiana, LLC | Indianapolis | Indiana | 46254 | — |
| University of South Alabama Mitchell Cancer Institute | Lafayette | Louisiana | 70503 | — |
| University of Maryland School of Med | Baltimore | Maryland | 21201 | — |
| Center for Cancer and Blood Disorders, PC | Bethesda | Maryland | 20817 | — |
| Henry Ford Medical Center - New Center One | Detroit | Michigan | 48202-268 | — |
| Minnesota Oncology Hematology, PA | Minneapolis | Minnesota | 55407 | — |
| Mayo Clinic | Rochester | Minnesota | 55905 | — |
| Midwest Physicians Group | Kansas City | Missouri | 64132 | — |
| Missouri Baptist Medical Center | St Louis | Missouri | 63131 | — |
| New Hampshire Oncology Hematology | Hooksett | New Hampshire | 03106 | — |
| Dartmouth Hitchcock Medical Center Norris Cotton Cancer Center | Lebanon | New Hampshire | 03756 | — |
| Englewood Hospital and Medical Center | Englewood | New Jersey | 07631 | — |
| Hematology Oncology Associates of CNY | East Syracuse | New York | 13057 | — |
| NYU Langone Arena Oncology | Lake Success | New York | 11042 | — |
| Clinical Research Alliance | New York | New York | 10021 | — |
| Alamance Regional Medical Cancer Center | Burlington | North Carolina | 27215-8700 | — |
| University of Cincinnatti | Cincinnati | Ohio | 45219 | — |
| Oncology Hematology Care | Cincinnati | Ohio | 45242 | — |
| Mark H Zangmeister Center | Columbus | Ohio | 43219 | — |
| Toledo Community Oncology Program | Toledo | Ohio | 43623 | — |
| Cancer Centers of Southwest Oklahoma | Lawton | Oklahoma | 73505 | — |
| North Bend Medical Center | Coos Bay | Oregon | 97420 | — |
| Northwest Cancer Specialists, P.C. - Hoyt | Portland | Oregon | 97213 | — |
| Providence Portland Medical Center | Portland | Oregon | 97213 | — |
| St Mary Medical Center | Langhorne | Pennsylvania | 19047 | — |
| Magee Women's Hospital | Pittsburgh | Pennsylvania | 15213 | — |
| South Carolina Oncology Associates | Columbia | South Carolina | 29210 | — |
| Chattanooga Oncology Hematology Associates | Chattanooga | Tennessee | 37404 | — |
| Sarah Cannon Cancer Center | Nashville | Tennessee | 37203 | — |
| Texas Oncology, PA | Dallas | Texas | 75231 | — |
| Texas Oncology, PA- Dallas | Dallas | Texas | 75246 | — |
| The Center for Cancer and Blood Disorders | Fort Worth | Texas | 76104 | — |
| UT Physicians General Medicine | Houston | Texas | 77030 | — |
| Cancer Care Centers of South Texas - Loop | San Antonio | Texas | 78217 | — |
| Texas Oncology P.A.- Tyler | Tyler | Texas | 75702 | — |
| Hematology Oncology Associates of Fredericksburg | Fredericksburg | Virginia | 22408 | — |
| Delta Hematologyoncology Associates | Portsmouth | Virginia | 23704 | — |
| Virginia Cancer Institute | Richmond | Virginia | 23230 | — |
| Medical Oncology Associates | Spokane | Washington | 99208 | — |
| Edwards Comprehensive Cancer Center | Huntington | West Virginia | 25701 | — |
| Saint Vincent Hospital | Green Bay | Wisconsin | 54301 | — |
| Columbia St Marys Cancer Center | Milwaukee | Wisconsin | 53211 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 76 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT01881230, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Feb 21, 2019 · Synced Oct 22, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT01881230 live on ClinicalTrials.gov.